foci佛慈品牌怎么样 申请店铺

我要投票 foci佛慈在阿胶行业中的票数:404 更新时间:2025-08-20
foci佛慈是哪个国家的品牌?「foci佛慈」是 兰州佛慈制药股份有限公司 旗下著名品牌。该品牌发源于甘肃,由创始人石爱国在2016期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力foci佛慈品牌出海!将品牌入驻外推网,定制foci佛慈品牌推广信息,可以显著提高foci佛慈产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

foci佛慈怎么样

兰州佛慈制药股份有限公司是一家具有近百年制药历史的市属国有控股上市公司和“中华老字号”企业(股票代码002644)。1929年创建于上海。1956年西迁兰州。2011年上市。目前,公司已发展成为集中药材种植与加工、天然药物与保健品研发、中药现代剂型及保健食品生产销售为一体的西北地区中医药行业的骨干企业。

截止目前,公司拥有4个生产基地、1个在建的医药科技工业园和2家全资子公司。拥有总资产100912万元、净资产71823万元。现有员工1400余人,其中各类工程技术人员400余名。拥有25条生产线,全部通过国家GMP认证,本部生产线还通过澳大利亚TGA组织、日本厚生省和乌克兰产品认证局的认证。现有药品生产批准文号345个,拥有定眩丸、参茸固本还少丸等10个独家产品,1个国家中药保护品种,9项发明专利,常年生产浓缩丸、大蜜丸、片剂等11种剂型的152种中西药产品。佛慈产品以“选材地道、工艺精良、疗效确切、服用方便”享誉中外。“佛慈”牌六味地黄丸、杞菊地黄丸、桂附地黄丸、逍遥丸、香砂养胃丸等系列产品多次被评为“甘肃名牌产品”。公司产品领域不断拓展,以阿胶、本草饮品“肖助理”等为代表的大健康产品陆续上市。“佛慈”注册商标为驰名保护,“岷山”商标为国家工商总局重点保护商标,“宝炉”、“善舒”为甘肃省著名商标。公司与中国中医科学院、瑞典斯德哥尔摩大学、清华大学、甘肃中医学院等多所国内外一流科研院所建立了良好的合作关系。现有甘肃省现代中药制剂工程技术研究中心和中瑞天然植物药和保健品研究中心两个重点研发平台。在漳县、临潭等地拥有当归规范化种植基地,总种植面积近1万亩。佛慈品牌在国内外具有良好的市场基础和广泛的影响力,国际国内销售网络日益完善,产品行销全国,出口到美国、澳大利亚、日本、香港等27个国家和地区,产品国外认证数、海外商标注册数、出口覆盖面、出口品种数长期位居同行业前列,多年来名列中国中成药出口企业十强。佛慈制药是国内首家申请欧盟药品注册的企业,如果浓缩当归丸在欧盟注册成功,并通过欧盟GMP认证,佛慈产品有望以药品身份进入欧盟市场,同时借此建立中药国际化标准。近期,佛慈制药被国家商务部等部委列入国家“首批中医药服务贸易先行先试骨干企业”名单。

近三年,公司将以新区项目为依托、以构建国际国内销售网络为重点,抢抓机遇,加快发展,力争在三年内实现营业收入10亿元,其中中成药出口1000万美元的目标。

Lanzhou foci Pharmaceutical Co., Ltd. is a municipal state-owned holding listed company and "China time honored brand" enterprise with nearly a hundred years of pharmaceutical history (Stock Code: 002644). Founded in Shanghai in 1929. In 1956, it moved west to Lanzhou. Listed in 2011. At present, the company has developed into a backbone enterprise in the Northwest China traditional Chinese medicine industry, which focuses on the cultivation and processing of traditional Chinese medicine, the research and development of natural drugs and health products, the production and sales of modern dosage forms of traditional Chinese medicine and health food. Up to now, the company has 4 production bases, 1 pharmaceutical science and Technology Industrial Park under construction and 2 wholly-owned subsidiaries. It has total assets of 1009.12 million yuan and net assets of 718.23 million yuan. There are more than 1400 employees, including more than 400 engineering and technical personnel. We have 25 production lines, all of which have passed the national GMP certification. Our production lines have also passed the certification of TGA in Australia, housheng in Japan and Ukrainian product certification authority. At present, there are 345 drug production approval numbers, 10 exclusive products such as Dingxuan pill, Shenrong Guben Huanshao pill, 1 National Traditional Chinese medicine protection variety, 9 invention patents, and 152 kinds of Chinese and Western medicine products with 11 dosage forms such as concentrated pill, big honey pill and tablet. Foci products are well-known at home and abroad for "authentic material selection, excellent technology, accurate curative effect and convenient use". "Foci" brand Liuwei Dihuang pill, Qiju Dihuang pill, Guifu Dihuang pill, Xiaoyao Pill, Xiangsha Yangwei pill and other series of products have been rated as "Gansu famous brand products" for many times. The product field of the company has been expanding, and the large health products represented by donkey hide gelatin and herbal drink "Xiao assistant" have been listed in succession. "Foci" registered trademark is well-known protection, "Minshan" trademark is the key protection trademark of the State Administration for Industry and commerce, "Baolu" and "Shanshu" are famous trademarks of Gansu Province. The company has established good cooperation with many domestic and foreign first-class scientific research institutes, such as Chinese Academy of traditional Chinese medicine, Stockholm University, Tsinghua University, Gansu College of traditional Chinese medicine, etc. At present, there are two key research and development platforms: Gansu Modern Chinese medicine preparation engineering technology research center and Zhongrui natural plant medicine and health product research center. In Zhangxian County, Lintan and other places, there are standardized planting bases for angelica, with a total planting area of nearly 10000 mu. Foci brand has a good market foundation and wide influence at home and abroad. Its international and domestic sales network is increasingly improved. Its products are sold all over the country and exported to 27 countries and regions such as the United States, Australia, Japan and Hong Kong. The number of foreign certification, overseas trademark registration, export coverage and export varieties of its products have long been in the forefront of the same industry. It has been ranked in the middle of China for many years Top 10 pharmaceutical export enterprises. Fosci pharmaceutical is the first enterprise applying for EU drug registration in China. If the concentrated Angelica pill is successfully registered in the EU and passes the EU GMP certification, fosci products are expected to enter the EU market as drugs, and at the same time establish international standards for traditional Chinese medicine. Recently, foci pharmaceutical has been listed in the list of "the first batch of backbone enterprises in the first trial of TCM service trade" by the Ministry of Commerce and other ministries. In the past three years, the company will take the new area project as the support, focus on the construction of international and domestic sales network, seize the opportunity, accelerate the development, and strive to achieve the business income of 1 billion yuan in three years, including the goal of 10 million US dollars for the export of Chinese patent medicine.

本文链接: https://brand.waitui.com/f19a649a3.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

江波龙:员工持股平台拟合计减持公司不超1.31%股份

36氪获悉,江波龙公告,龙熹一号、龙熹二号、龙熹三号、龙舰管理、龙熹五号(统称“员工持股平台”)合计持有公司16.53%股份,计划在2025年9月11日至12月10日期间通过集中竞价交易方式和大宗交易方式合计减持公司股份不超过548万股(不超过公司总股本的1.31%)。

2小时前

云南锗业:公司及鑫耀公司目前并无6英寸磷化铟晶片规模化量产的具体计划

36氪获悉,云南锗业发布股票交易异常波动公告,公司了解到,近期有国内研发机构发布了其在6英寸磷化铟外延生长工艺领域实现了技术突破相关事宜。就控股子公司鑫耀公司而言,在2-4英寸规格的磷化铟晶片量产后,为应对未来的市场需求,对更大尺寸的产品开展了研究开发,但从研发到规模化生产尚存在较大不确定性。公司及鑫耀公司目前并无6英寸磷化铟晶片规模化量产的具体计划,下一步在市场与需求风险、技术风险等可控的前提下,公司方会考虑相关计划,如有相关计划,公司会按规定进行公开披露。

2小时前

胜宏科技:向香港联交所递交H股发行并上市申请并刊发申请资料

36氪获悉,胜宏科技公告,公司已于2025年8月20日向香港联交所递交了发行境外上市股份(H股)并在香港联交所主板挂牌上市的申请,并于同日在香港联交所网站刊登了本次发行的申请资料。该申请资料为草拟版本,其所载资料可能会适时作出更新及修订。公司本次发行尚需取得相关政府机关、监管机构、证券交易所的批准、核准或备案。

2小时前

永辉超市:上半年净亏损2.41亿元

36氪获悉,永辉超市公告,公司上半年实现营业总收入299.48亿元,同比下降20.73%;净亏损2.41亿元,上年同期盈利2.75亿元。

2小时前

摩根大通与三菱日联接近达成220亿美元的得州数据中心融资协议

英国《金融时报》周三报道,摩根大通和日本三菱日联金融集团正就为得克萨斯州一个数据中心承销220亿美元贷款展开谈判。报道称,该规划中的园区将由Vantage Data Centers所有,这是一家由银湖资本和资产管理公司DigitalBridge 控股的数字基础设施企业。报道还指出,银湖资本和DigitalBridge将合计承诺30亿美元股权,助力该数据中心园区的建设。(新浪财经)

2小时前

本页详细列出关于foci佛慈的品牌信息,含品牌所属公司介绍,foci佛慈所处行业的品牌地位及优势。
咨询